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Abstract
We hypothesized that an increased, incomplete fatty acid beta-oxidation in
mitochondria could be part of the metabolic events leading to insulin resis-
tance and thereby an increased type 2 diabetes risk in low birth weight (LBW)
compared with normal birth weight (NBW) individuals. Therefore, we mea-
sured fasting plasma levels of 45 acylcarnitine species in 18 LBW and 25 NBW
men after an isocaloric control diet and a 5-day high-fat, high-calorie diet.
We demonstrated that LBW men had higher C2 and C4-OH levels after the
control diet compared with NBW men, indicating an increased fatty acid
beta-oxidation relative to the tricarboxylic acid cycle flux. Also, they had
higher C6-DC, C10-OH/C8-DC, and total hydroxyl-/dicarboxyl-acylcarnitine
levels, which may suggest an increased fatty acid omega-oxidation in the liver.
Furthermore, LBW and NBW men decreased several acylcarnitine levels in
response to overfeeding, which is likely a result of an upregulation of fatty
acid oxidation due to the dietary challenge. Moreover, C10-OH/C8-DC and
total hydroxyl-/dicarboxyl-acylcarnitine levels tended to be negatively associ-
ated with the serum insulin level, and the total hydroxyl-/dicarboxyl-acylcarni-
tine level additionally tended to be negatively associated with the hepatic
insulin resistance index. This indicates that an increased fatty acid omega-oxi-
dation could be a compensatory mechanism to prevent an accumulation of
lipid species that impair insulin signaling.
Introduction
Low birth weight (LBW) individuals have an increased
risk of developing obesity, cardiovascular disease, and
type 2 diabetes, compared with normal birth weight
(NBW) individuals, when exposed to an affluent life style
such as overfeeding (Ravelli et al. 1976; Hales et al. 1991;
Barker et al. 1993; Harder et al. 2007). In a short-term
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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high-fat overfeeding study in young, healthy LBW and
NBW men, we have shown that LBW men display a
number of metabolic abnormalities relevant to the patho-
physiology of type 2 diabetes, including a decreased hepatic
insulin sensitivity (Brons et al. 2008) prior to, and develop-
ment of a decreased peripheral insulin sensitivity in
response to a high-fat, high-calorie diet intervention (Brons
et al. 2012). Furthermore, we have shown that LBW men
exhibit an increased fatty acid oxidation rate, but an unal-
tered total energy expenditure, during night time compared
with NBW men (Brons et al. 2013). However, the extent to
which the disproportionately increased fatty acid oxidation
rate could contribute to the decreased insulin sensitivity in
LBW men as a result of a differential and potentially
incomplete fatty acid oxidation remains to be studied.
High-fat overfeeding and an increased lipid exposure to
skeletal muscle has been shown to lead to an increased
expression of genes in the fatty acid beta-oxidation path-
way, including the gene encoding carnitine palmitoyl-
transferase I (CPT-I) that catalyzes the condensation of
activated long-chain fatty acids (acyl-CoAs) to carnitine
to form acylcarnitines and thereby regulates the entry of
these acyl-CoAs into the mitochondrial matrix (Koves
et al. 2005; Muoio and Newgard 2006; Turner et al.
2007). Also, in the state of high-fat overfeeding, an
increased beta-oxidation has been suggested to not neces-
sarily be matched by increased tricarboxylic acid (TCA)
cycle and electron transport chain fluxes, which results in
an incomplete fatty acid oxidation (Koves et al. 2005,
2008; Muoio and Newgard 2006, 2008b). This leads to an
accumulation of acylcarnitines and reactive oxygen species
that may contribute to metabolic stress and thereby ulti-
mately impair insulin signaling (Bloch-Damti and Bashan
2005; Adams et al. 2009; Rutkowsky et al. 2014; Aguer
et al. 2015). In addition to an incomplete beta-oxidation,
increased intracellular concentrations of long-chain acyl-
CoAs may lead to an increased lipogenesis, hereunder the
synthesis of lipid species that impair insulin signaling
(Muoio and Newgard 2008b). This metabolic fate of
long-chain acyl-CoAs has been especially described in the
context of high-fat diet-induced hepatic insulin resistance.
Actually, high-fat overfeeding has been proposed to lead
to malonyl-CoA induced inhibition of CPT-I activity in
the liver, and a following diversion of long-chain acyl-
CoAs away from beta-oxidation and toward other meta-
bolic fates in the cytosol, including lipogenesis (Muoio
and Newgard 2008a,b). However, studies also point to
that an increased lipid exposure to the liver leads to a
simultaneously increased beta-oxidation and incorpora-
tion of long-chain acyl-CoAs into lipids (Ciapaite et al.
2011).
Incomplete fatty acid beta-oxidation downstream of
CPT-I is reflected by elevated plasma acylcarnitine levels
(Koves et al. 2008), as acyl-CoAs in the mitochondrial
matrix can be converted into acylcarnitines that subse-
quently are transported through the mitochondrial mem-
branes and thereafter from the cytosol to the blood (Koves
et al. 2008; Millington and Stevens 2011; Violante et al.
2013). Actually, higher plasma acylcarnitine levels have
been found in adults with prediabetes and type 2 diabetes
(Adams et al. 2009; Mihalik et al. 2010; Ha et al. 2012; Mai
et al. 2013). Also, defects in specific steps of beta-oxidation
can be revealed by altered acylcarnitine levels, as made use
of in the diagnosis of inborn errors in fatty acid metabo-
lism (Millington et al. 1990; Chace et al. 2001, 2003).
Moreover, the involvement of other metabolic pathways
upstream of beta-oxidation may be reflected in the compo-
sition and concentrations of acylcarnitine species (Koves
et al. 2008). Thus, an incomplete beta-oxidation give rise
to even-chain C4–C22 acylcarnitine species, and amino
acid catabolism is a source for C3, C4, and C5 species
(Koves et al. 2008). These pathways are, together with glu-
cose oxidation, in addition sources of acetylcarnitine, C2,
when acetyl-CoA is generated in excess in the mitochon-
drial matrix relative to the flux into the TCA cycle (Zam-
mit 1999; Koves et al. 2008). In this situation, carnitine
acetyl-CoA transferase (CrAT) catalyzes the transfer of
acetyl-CoA to carnitine to form acetylcarnitine, which is
subsequently transported to the cytosol (Zammit 1999;
Muoio Deborah et al. 2012). An accumulation of acyl-
CoAs in the cytosol due to an incomplete beta-oxidation
may lead to an increased fatty acid omega-oxidation in the
endoplasmic reticulum of mainly the liver (Bjorkhem 1976;
Reddy and Hashimoto 2001; Patsouris et al. 2006). This
latter is expected to be reflected in higher plasma hydro-
xyl-/dicarboxyl-acylcarnitine levels (Reddy and Hashimoto
2001; Houten et al. 2012).
We hypothesized that an increased, incomplete fatty
acid beta-oxidation could contribute to the impaired
insulin sensitivity in LBW individuals, reflected by ele-
vated plasma acylcarnitine levels. Accordingly, we ana-
lyzed fasting plasma levels of 45 acylcarnitine species,
including even-chain C2–C22 species, odd-chain C3–C7
species, and hydroxyl-/dicarboxyl-species, in LBW and
NBW men following an isocaloric control diet and a
5-day high-fat, high-calorie diet.
Materials and Methods
Study population
Forty-six young (23–27 years of age), healthy men were
recruited from the Danish National Birth Registry accord-
ing to birth weight. All individuals were born at term (39–
41 weeks of gestation) and in Copenhagen in the period
1979–1980. LBW was defined as a birth weight below the
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10th percentile, as earlier studies have shown that individu-
als within this range have an increased risk of developing
type 2 diabetes (Jaquet et al. 2000; Jensen et al. 2002), and
NBW was defined as a birth weight within the 50th–90th
percentile range. Among the recruited men, 20 had LBW
(2717  268 g) and 26 had NBW (3901  207 g). Fur-
thermore, all participants were ensured to not have a family
history of diabetes in two generations, not have a body
mass index (BMI) greater than 30 kg/m2, not perform
strenuous physical activity more than 10 h per week, not
take pharmaceuticals that affect metabolism, and not have
an abuse of alcohol or drugs.
Study design
Diet interventions
All individuals were in a randomized crossover setup
standardized with respect to diet and physical activity and
following given a 3-day control diet and a 5-day high-fat,
high-calorie diet separated by a 6–8 weeks wash-out per-
iod. Energy requirements of the individual subjects were
calculated from a World Health Organization equation for
men less than 30 years of age and a physical activity
level of 1.4 corresponding to a low physical activity
(WHO, 2001). The control diet was composed to reflect
a habitual, weight-maintaining diet (2819  238 kcal/
11,800  1000 kJ) with 15% of the total energy from
protein, 50% from carbohydrate, and 35% from fat, and
the high-fat, high-calorie diet was prepared to contain
50% extra calories (4228  334 kcal/17,700  1,400 kJ)
with 7.5% of the total energy from protein, 32.5% from
carbohydrate, and 60% from fat (Table S1). Both diets
were provided as five daily servings with 25% of the total
energy from breakfast, 10% from morning snack, 25%
from lunch, 10% from afternoon snack, and 30% from
dinner, and the meals were identical from day to day.
Dietary calculations were made in Dankost Pro
(http://dankost.dk/english) (The National Food Agency,
Copenhagen, Denmark).
Clinical examinations
Study activities were carried out over 3 days, with the
first of these days being placed 1 or 3 days after the
start of the control and high-fat, high-calorie diet inter-
vention, respectively. Anthropometry was performed on
the first study day. An intravenous glucose tolerance
test (IVGTT) and a hyperinsulinemic-euglycemic clamp
were carried out in the morning on the third study
day following an overnight fast to assess insulin secre-
tion and sensitivity, as previously described (Brons et al.
2008, 2012). Furthermore, calorimetry was performed
throughout 24 h from the first to second study day by
use of a respiratory chamber and in the basal and insu-
lin-stimulated steady-state periods of the clamp to eval-
uate substrate utilization rates and energy expenditures,
as previously described (Brons et al. 2012, 2013, 2015).
Blood samples were collected prior to and during the
clamp.
Laboratory measurements
Acylcarnitine analyses
Acylcarnitine analyses were performed on EDTA-plasma
samples collected following an overnight fast (10.00
PM–7.00 AM) and immediately prior to the clamp exami-
nation. These analyses included a semi-quantitative
determination of 45 a priori selected acylcarnitine spe-
cies or sets of species (ions with equal mass), noted in
this text by their acyl group in accordance to its car-
bon chain length (e.g., C16), possible double bonds
(e.g., C16:1), and possible hydroxyl- or a second car-
boxyl-group (e.g., C16-OH or C16-DC, respectively)
(Table 3, Table S2), and were performed by use of
sample preparation procedures and flow injection-tan-
dem mass spectrometry (MS/MS), as previously
described (An et al. 2004; Ferrara et al. 2008; Milling-
ton and Stevens 2011). In brief, plasma samples were
spiked with a selection of deuterium-labeled acylcar-
nitine standards, including D3-C2, D3-C3, D3-C4, D9-
C5, D3-C8, and D3-C16 carnitines (Cambridge Isotope
Laboratories, Andover, MA). Following, proteins were
removed by precipitation with methanol, and the super-
natants were then transferred to a 96-well plate, evapo-
rated to dryness under nitrogen gas, and incubated
with either acidified methanol or butanol to form
methyl and butyl ester derivatives of the acylcarnitines,
respectively. After this, the reagents were evaporated to
dryness under nitrogen gas, and the residues were
redissolved in 85:15 (v/v) methanol:water. Subsequently,
the samples were introduced into a Quattro Micro MS/
MS system (Waters, Milford, MA) equipped with a
model HTS-PAL autosampler (Leap Technologies, Car-
rboro, NC) and a model 1100 HPLC solvent delivery
system (Agilent Technologies, Santa Clara, CA). Mass
spectra of the acylcarnitine esters were obtained by pos-
itive precursor ion scanning of m/z 99 and m/z 85 for
methyl or butyl esters, respectively. Following, acylcar-
nitines were identified from the peaks of these deriva-
tives and quantified from the ratio of their molecular
signals to respective internal standards (Table S2). Some
acylcarnitine species shared the same internal standard
due to the limited number of commercially available
analytical standards. Addition of more internal
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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standards, however, does not appear to significantly
improve the analytical precision (Millington and Stevens
2011). Mass spectra were analyzed by use of MassLynx
4.0 (Waters). Acylcarnitine analyses were performed in
The Sarah W. Stedman Nutrition and Metabolism Cen-
ter Metabolomics/Biomarker Core Laboratory, Duke
University, Durham, NC. The laboratory was blinded to
the birth weight of the individuals.
Ethical approval
All study procedures were in accordance with the principles
of The Declaration of Helsinki and were approved by The
Regional Research Ethics Committee of Copenhagen, Den-
mark. Also, all participants were provided with written
information on the study purpose and procedures and
signed an informed consent prior to their participation.
Table 1. Clinical characteristics of low (LBW) and normal birth weight (NBW) men following the control (C) and high-fat, high-calorie (O)
diets.
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(Mean  SD)
O
(Mean  SD)
PNBW C
(Mean  SD)
O
(Mean  SD)
PLBW PC PO PD
Anthropometry
Birth weight (g) 3901  207 – – 2717  268 – – ≤0.001 – –
Weight (kg) 78.4  9.3 78.6  9.7 n.s. 77.1  11.3 77.1  11.4 n.s. n.s. n.s. n.s.
Height (m) 1.83  0.07 – – 1.77  0.05 – – ≤0.05 – –
Body mass index (kg/m2) 23.3  2.4 23.3  2.5 n.s. 24.6  3.8 24.6  3.8 n.s. n.s. n.s. n.s.
Lipid profiling
P-TG (mmol/L) 0.92  0.35 0.73  0.35 ≤0.05 1.07  0.37 0.72  0.24 ≤0.01 n.s. n.s. n.s.
P-CHOL (mmol/L) 4.36  0.83 4.18  0.82 n.s. 4.36  0.78 4.27  0.79 n.s. n.s. n.s. n.s.
P-VLDL-CHOL (mmol/L) 0.42  0.16 0.33  0.16 ≤0.05 0.49  0.18 0.32  0.12 ≤0.01 n.s. n.s. n.s.
P-LDL-CHOL (mmol/L) 2.51  0.72 2.28  0.78 ≤0.05 2.69  0.76 2.57  0.80 n.s. n.s. n.s. n.s.
P-HDL-CHOL (mmol/L) 1.40  0.22 1.56  0.25 ≤0.01 1.19  0.23 1.38  0.28 ≤0.01 ≤0.01 ≤0.05 n.s.
Clamp
Basal
B-Glucose (mmol/L) 4.59  0.47 5.05  0.40 ≤0.001 4.97  0.48 5.18  0.34 ≤0.05 ≤0.01 n.s. n.s.
S-Insulin (pmol/L) 30.2  14.7 43.4  29.2 ≤0.05 41.7  14.6 44.7  21.9 n.s. ≤0.01 n.s. n.s.
S-C-peptide (pmol/L) 408  146 529  260 ≤0.01 492  116 539  172 n.s. ≤0.05 n.s. n.s.
P-NEFA (lmol/L) 334  136 205  82 ≤0.001 406  200 188  91 ≤0.001 n.s. n.s. n.s.
HGP (mg/kgFFM/min) 2.21  0.48 2.85  0.99 ≤0.01 2.40  0.5 2.48  0.5 n.s. n.s. n.s. ≤0.05
Hepatic IR (mg/kgFFM/
minpmol/L)
68.7  34.1 113.7  61.5 ≤0.001 102.3  50.8 108.7  55.5 n.s. ≤0.05 n.s. ≤0.05
GOX (mg/kgFFM/min) 2.34  0.76 2.43  0.71 n.s. 1.95  0.78 2.20  0.56 n.s. n.s. n.s. n.s.
FOX (mg/kgFFM/min) 1.00  0.38 1.02  0.33 n.s. 1.11  0.53 1.17  0.33 n.s. n.s. n.s. n.s.
Insulin-stimulated
P-NEFA (lmol/L) 9.29  4.39 12.42  6.43 ≤0.01 9.56  5.03 14.39  7.76 ≤0.01 n.s. n.s. n.s.
M-value
(mg/kgFFM/min)
13.73  2.32 13.29  3.32 n.s. 13.47  3.14 11.89  3.57 ≤0.05 n.s. n.s. n.s.
GOX (mg/kgFFM/min) 5.18  0.82 5.04  0.98 n.s. 4.95  0.92 4.78  0.82 n.s. n.s. n.s. n.s.
FOX (mg/kgFFM/min) 0.01  0.25 0.17  0.33 n.s. 0.13  0.46 0.37  0.35 ≤0.05 n.s. ≤0.05 n.s.
IVGTT
FPIR (pmol/L) 1894  1431 2604  1793 ≤0.001 2135  1034 2750  1509 ≤0.01 n.s. n.s. n.s.
Hepatic DI 0.38  0.63 0.25  0.21 n.s. 0.21  0.11 0.24  0.13 n.s. n.s. n.s. n.s.
Peripheral DI 0.29  0.19 0.35  0.20 ≤0.05 0.33  0.13 0.32  0.17 n.s. n.s. n.s. n.s.
Data are presented as mean  SD. P-values from Student’s t-tests are presented unadjusted for multiple comparisons, and P-values ≤0.5 are
considered statistically significant. PNBW and PLBW: O versus C diet within each birth weight group, PC and PO: LBW versus NBW individuals
within each diet, PD: LBW versus NBW individuals on response values. n.s.: Not significant. P-values ≤0.05 are marked in bold. Abbreviations:
B, Blood; CHOL, Cholesterol; DI, Disposition index; FFM, Fat free mass; FOX, Fatty acid oxidation; FPIR, First-phase insulin response; GOX, Glu-
cose oxidation; HDL, High-density lipoprotein; HGP, Hepatic glucose production; IR, Insulin resistance; IVGTT, Intravenous glucose tolerance
test; LDL, Low-density lipoprotein; NEFA, Nonesterified fatty acid; P, Plasma; S, Serum; TG, Triacylglycerol; VLDL, Very low-density lipoprotein.
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Statistical analyses
Acylcarnitine levels and their relation to
physiological measures
Differences in plasma acylcarnitine levels between NBW
and LBW individuals within each diet or between the
control and high-fat, high-calorie diets within each birth
weight group were assessed from Student’s unpaired or
paired t-test (for normally distributed values), respec-
tively, or Wilcoxon ranked-sum or signed-rank test (for
not normally distributed values), respectively. Prior to
these tests, statistical outliers (1.5 interquartile range)
were removed from the dataset. Also, values below the
lower limit of detection were replaced by 0.5 times this
limit, which was defined as the minimum value for the
actual metabolite. Following, outliers were replaced by the
mean value within the group. Normal distribution of
values (variables or differences between variables,
respectively) was evaluated from Shapiro–Wilk test.
Finally, after P-values were calculated, adjustment for
multiple testing was done by calculating false discovery
rates, Q-values, by the Benjamini and Hochberg method
(Benjamini and Hochberg 1995). Data in Table 3 are pre-
sented as mean value plus or minus standard deviation
(SD) together with P- and Q-values. P-values ≤0.05 were
considered statistically significant if their corresponding
Q-values were ≤0.1. Student’s t-tests and Wilcoxon tests
were performed in SAS Enterprise Guide 6.1 (SAS
Institute, Cary, NC), and Benjamini and Hochberg cor-
rections were performed in R 3.1.0 (https://www.r-
project.org/).
Associations between plasma acylcarnitine levels and
physiological measures were assessed from linear regres-
sion analyses. These analyses were performed on the
pooled dataset of LBW and NBW individuals and were
adjusted for age, BMI, and birth weight group. Only acyl-
carnitine levels that significantly differed between NBW
Table 2. Glucose, fatty acid, and protein oxidation rates and total energy expenditures in low (LBW) and normal birth weight (NBW) men dur-
ing the control (C) and high-fat, high-calorie (O) diets.
(kJ/min)
LBW versus NBW
(n = 26)
LBW versus NBW
(C: n = 20, O: n = 18)
LBW versus NBW
(n = 20/n = 18,
n = 26)
C
(Mean  SEM)
O
(Mean  SEM)
PNBW C
(Mean  SEM)
O
(Mean  SEM)
PLBW PC PO PD
Calorimetry 24 h
GOX
Day 3.85  0.17 3.50  0.08 0.0297 3.69  0.16 3.30  0.14 0.0609 0.52 0.19 0.94
Night 1.97  0.10 2.07  0.07 0.3126 1.78  0.09 1.84  0.10 0.3391 0.18 0.06 0.97
Sleep 1.91  0.12 1.89  0.08 0.9131 1.58  0.10 1.77  0.11 0.0836 0.05 0.37 0.21
24 h 3.10  0.13 2.93  0.07 0.1510 2.92  0.13 2.73  0.09 0.2620 0.34 0.09 0.97
FOX
Day 3.34  0.16 4.23  0.14 <0.0001 3.46  0.14 4.52  0.21 <0.0001 0.60 0.23 0.60
Night 2.34  0.10 2.80  0.10 0.0005 2.60  0.08 3.06  0.12 0.0023 0.07 0.10 0.93
Sleep 2.14  0.14 2.72  0.12 0.0001 2.50  0.09 2.87  0.13 0.0221 0.05 0.38 0.40
24 h 2.92  0.12 3.63  0.12 <0.0001 3.11  0.11 3.91  0.14 <0.0001 0.24 0.14 0.76
POX
Day 1.13  0.04 0.79  0.03 <0.0001 1.08  0.04 0.74  0.04 <0.0001 0.48 0.32 0.71
Night 1.13  0.04 0.79  0.03 <0.0001 1.08  0.04 0.74  0.04 <0.0001 0.48 0.32 0.71
Sleep 1.13  0.04 0.79  0.03 <0.0001 1.08  0.04 0.74  0.04 <0.0001 0.48 0.32 0.71
24 h 1.13  0.04 0.79  0.03 <0.0001 1.08  0.04 0.74  0.04 <0.0001 0.48 0.32 0.71
EE
Day 8.32  0.15 8.52  0.13 0.0142 8.24  0.16 8.56  0.18 0.0021 0.71 0.86 0.39
Night 5.43  0.09 5.65  0.10 0.0001 5.46  0.11 5.66  0.13 0.0017 0.82 0.97 0.99
Sleep 5.17  0.09 5.39  0.09 0.0010 5.16  0.11 5.30  0.13 0.0009 0.96 0.93 0.82
24 h 7.14  0.12 7.36  0.12 0.0005 7.12  0.14 7.38  0.15 0.0008 0.88 0.90 0.55
Data are presented as mean  SEM. P-values from Student’s t-tests are presented unadjusted for multiple comparisons, and P-values ≤0.5 are
considered statistically significant. PNBW and PLBW: O versus C diet within each birth weight group, PC and PO: LBW versus NBW individuals
within each diet, PD: LBW versus NBW individuals on response values. P-values ≤0.05 are marked in bold. P-values on intervention effects are
presented here for the first time. Details on the measurements have been described in previous articles (Brons et al. 2013, 2015). Abbrevia-
tions: EE, Energy expenditure; FOX, Fatty acid oxidation; GOX, Glucose oxidation; POX, Protein oxidation.
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Table 3. Plasma acylcarnitine levels in low (LBW) and normal birth weight (NBW) men following the control (C) and high-fat, high-calorie (O)
diets.
(lmol/L)
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(Mean  SD)
O
(Mean  SD)
PNBW
QNBW
C
(Mean  SD)
O
(Mean  SD)
PLBW
QLBW
PC
QC
PO
QO
PD
QD
Lipid profiling
Acylcarnitines
C2 4.771  0.797 3.985  0.738 0.0015 5.985  1.587 4.393  0.784 0.0007 0.0066 0.0886 0.0595
0.0095 0.0046 0.0660
C3 0.317  0.102 0.273  0.075 0.0487 0.298  0.103 0.259  0.054 0.1582 0.5694 0.5058 0.8998
0.1131
C4/Ci4 0.146  0.057 0.126  0.037 0.1054 0.162  0.047 0.123  0.049 0.0082 0.3243 0.7823 0.2661
0.0291
C5:1 0.088  0.040 0.073  0.030 0.1275 0.084  0.026 0.088  0.039 0.5944 0.7246 0.1369 0.2252
C5’s 0.122  0.032 0.116  0.030 0.5296 0.129  0.029 0.128  0.048 0.9683 0.4736 0.3526 0.7215
C4-OH 0.038  0.016 0.034  0.010 0.3581 0.054  0.019 0.030  0.012 <0.0001 0.0039 0.2229 0.0006
0.0020 0.0520 0.0222
C6 n.d. n.d. – n.d. n.d. – – – –
C5-OH/C3-DC 0.118  0.047 n.d. – 0.114  0.054 n.d. – 0.8051 – –
C4-DC/Ci4-DC 0.033  0.013 0.036  0.017 0.5226 0.042  0.013 0.044  0.009 0.5642 0.0328 0.0431 0.9323
0.1966 0.6667
C8:1 0.100  0.032 0.190  0.054 <0.0001 0.116  0.032 0.222  0.067 <0.0001 0.1354 0.0957 0.3314
0.0013 0.0020
C8 0.122  0.049 0.105  0.030 0.1010 0.127  0.042 0.111  0.030 0.1193 0.6921 0.5241 0.9872
C5-DC 0.048  0.012 0.047  0.015 0.7495 0.050  0.013 0.050  0.020 0.9169 0.7073 0.5795 0.7856
C8:1-OH/C6:1-DC 0.037  0.009 0.062  0.023 <0.0001 0.034  0.014 0.060  0.023 0.0013 0.3884 0.5660 0.5679
0.0013 0.0072
C6-DC 0.064  0.022 0.080  0.022 0.0039 0.084  0.017 0.089  0.019 0.4862 0.0032 0.1926 0.1504
0.0165 0.0520
C10:3 n.d. 0.088  0.031 – 0.053  0.034 0.102  0.035 0.0005 – 0.1965 –
0.0039
C10:2 n.d. n.d. – n.d. n.d. – – – –
C10:1 0.136  0.053 0.121  0.037 0.2216 0.138  0.039 0.131  0.023 0.5697 0.9120 0.3127 0.5908
C10 0.347  0.160 0.311  0.117 0.3218 0.297  0.125 0.287  0.102 0.8378 0.2736 0.4908 0.6401
C7-DC n.d. n.d. – n.d. n.d. – – – –
C8:1-DC 0.024  0.009 0.028  0.012 0.1054 0.028  0.012 0.026  0.007 0.5224 0.1744 0.4497 0.1216
C10-OH/C8-DC 0.033  0.014 0.032  0.010 0.6502 0.048  0.015 0.036  0.010 0.0048 0.0025 0.1459 0.0585
0.0208 0.0520
C12:1 0.093  0.040 0.067  0.017 0.0074 0.109  0.039 0.072  0.016 0.0005 0.1226 0.3820 0.3802
0.0263 0.0039
C12 0.082  0.037 0.083  0.031 0.9887 0.089  0.028 0.084  0.024 0.5806 0.5344 0.8875 0.6768
C12-OH/C10-DC 0.008  0.004 0.006  0.003 0.0327 0.007  0.002 0.006  0.002 0.2281 0.5988 0.4714 0.3471
0.0866
C14:2 0.026  0.015 0.018  0.009 0.0076 0.031  0.012 n.d. – 0.3231 – –
0.0263
C14:1 0.056  0.018 0.049  0.020 0.1900 0.071  0.025 0.049  0.016 0.0054 0.0308 0.8905 0.1259
0.0211 0.1966
C14 n.d. n.d. – n.d. 0.026  0.011 – – – –
C14:1-OH/C12:1-DC 0.012  0.006 0.011  0.005 0.3108 0.014  0.006 0.012  0.005 0.2743 0.2065 0.2887 0.7372
C14-OH/C12-DC 0.008  0.004 0.007  0.003 0.1782 0.009  0.002 0.008  0.004 0.7148 0.4479 0.1429 0.5903
C16:2 0.006  0.003 0.005  0.003 0.0199 0.006  0.002 0.004  0.003 0.0251 0.9316 0.2900 0.3964
0.0630 0.0699
C16:1 0.019  0.009 0.010  0.005 <0.0001 0.020  0.009 0.011  0.007 0.0121 0.6717 0.5271 0.9987
0.0013 0.0393
C16 0.077  0.012 0.066  0.008 0.0006 0.083  0.016 0.072  0.015 0.0133 0.1681 0.1796 0.9050
0.0057 0.0399
C16:1-OH/C14:1-DC 0.008  0.003 0.006  0.003 0.0022 0.008  0.003 0.006  0.003 0.0912 0.7204 0.8956 0.8272
(Continued)
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and LBW individuals after the control or high-fat, high-
calorie diet were included in the analyses. Data in Tables
4, 5, and 6 are presented as slope plus or minus SD
together with P- and Q-values. P-values were considered
statistically significant as described above. Linear regres-
sion analyses were performed in R.
Results
Eighteen LBW and 25 NBW men were included in this
study. Two LBW individuals of the recruited participants
failed to consume all the food provided during the high-
fat, high-calorie diet, and a NBW subject felt discomfort
in connection with the clamp after the control diet and
therefore did not further participate in this test in either
the control or high-fat, high-calorie diet study part.
Clinical characteristics
Low birth weight and NBW men displayed differences in
body composition and glucose and lipid metabolism after
the control and high-fat, high-calorie diets, and both
birth weight groups showed changes in metabolism in
response to the dietary challenge, as previously reported
(Brons et al. 2008, 2012, 2013, 2015). A selection of vari-
ables that provide background for the current findings is
shown in Tables 1 and 2 and also presented here.
Low birth weight men had higher fasting blood glucose
and serum insulin levels after the control diet compared
with NBW men (Table 1). Also, LBW and NBW men
both increased the fasting blood glucose level and
decreased the fasting plasma nonesterified fatty acid level
in response to overfeeding (Table 1). NBW men addition-
ally increased the fasting serum insulin level due to this
challenge. LBW and NBW men did not show differences
in basal glucose or fatty acid oxidation rates after the
control or high-fat, high-calorie diet when evaluated from
the indirect calorimetry examination in connection with
the clamp on the last study day, and they also did not
change these rates in response to overfeeding (Table 1).
However, when studied during the 24 h calorimetry dur-
ing the interventions, LBW men had a higher fatty acid
Table 3. Continued.
(lmol/L)
NBW
(n = 25)
LBW
(n = 18)
LBW versus NBW
(n = 18, n = 25)
C
(Mean  SD)
O
(Mean  SD)
PNBW
QNBW
C
(Mean  SD)
O
(Mean  SD)
PLBW
QLBW
PC
QC
PO
QO
PD
QD
0.0119
C16-OH/C14-DC 0.005  0.002 0.004  0.002 0.2545 0.004  0.002 0.005  0.003 0.3113 0.2796 0.3719 0.1247
C18:2 0.032  0.006 0.033  0.008 0.6651 0.036  0.013 0.036  0.007 0.9486 0.3153 0.2563 0.8531
C18:1 0.096  0.021 0.076  0.016 0.0012 0.110  0.024 0.083  0.020 0.0002 0.0488 0.1802 0.4145
0.0091 0.0026 0.2440
C18 0.049  0.008 0.042  0.011 0.0342 0.051  0.011 0.045  0.012 0.0307 0.4460 0.3463 0.7884
0.0866 0.0798
C18:2-OH 0.005  0.004 n.d. – 0.005  0.005 0.004  0.003 0.2252 0.7582 – –
C18:1-OH/C16:1-DC 0.006  0.002 0.004  0.002 0.0028 0.007  0.004 0.003  0.002 0.0015 0.3136 0.3860 0.1537
0.0133 0.0073
C18-OH/C16-DC 0.006  0.003 0.005  0.003 0.6185 0.007  0.003 0.006  0.002 0.2424 0.0344 0.2525 0.4401
0.1966
C20:4 0.006  0.003 0.006  0.004 0.6264 0.007  0.003 0.006  0.004 0.5415 0.5908 0.8081 0.8447
C20 0.004  0.002 0.005  0.002 0.4190 0.006  0.003 0.005  0.003 0.3517 0.1378 0.6414 0.1991
C20:1-OH/C18:1-DC 0.008  0.004 0.006  0.002 0.0506 0.007  0.003 0.007  0.003 0.8446 0.6730 0.1213 0.1343
C20-OH/C18-DC 0.008  0.003 0.009  0.004 0.4546 0.009  0.003 0.010  0.002 0.6724 0.2669 0.5315 0.7204
C22 0.004  0.002 0.005  0.002 0.0243 0.005  0.003 0.006  0.002 0.2680 0.2850 0.5532 0.6343
0.0710
Total levels
OH/DC 0.345  0.061 0.377  0.075 0.0511 0.412  0.057 0.397  0.041 0.3833 0.0007 0.2679 0.0488
Non-OH/DC 6.674  0.913 5.746  0.865 0.0006 7.928  1.822 6.215  0.888 0.0008 0.0049 0.0901 0.0901
All 7.019  0.945 6.122  0.905 0.0011 8.340  1.854 6.614  0.885 0.0009 0.0039 0.0836 0.0790
Data are presented as mean  SD, unless the acylcarnitine was not detected (n.d.) in more than 25% of the samples. P-values ≤0.05 are pre-
sented together with Q-values, and P-values ≤0.05 with corresponding Q-values ≤0.1 are considered statistically significant. PNBW and PLBW, O
versus C diet within each birth weight group; PC and PO, LBW versus NBW individuals within each diet; PD, LBW versus NBW individuals on
response values. P-values ≤0.05 and Q-values ≤0.1 are marked in bold.
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Table 4. Associations between C2 or C4-OH level and physiological measures following the control (C) and high-fat, high-calorie (O) diets
and between response values (D).
C2
(Slope, SD, P, Q)
C4-OH
(Slope, SD, P, Q)
C O D C O D
Lipid profiling
P-TG 0.050 0.103 0.057 1.540 1.123 0.926
0.039 0.054 0.045 2.817 3.623 3.132
0.2140 0.0683 0.2079 0.5880 0.7580 0.7691
Clamp
Basal
B-Glucose 0.009 0.023 0.053 0.881 5.257 0.954
0.059 0.078 0.047 4.160 4.786 3.577
0.8855 0.7649 0.2696 0.8335 0.2790 0.7912
S-Insulin 0.246 2.109 1.451 99.78 358.9 165.8
1.389 2.893 1.368 96.49 178.0 100.4
0.8604 0.4713 0.2970 0.3080 0.0522 0.1080
P-NEFA 52.92 29.97 43.43 650.3 521.6 2038
18.70 17.25 17.79 1335 1136 1274
0.0075 0.0908 0.0197 0.6290 0.6490 0.1183
0.1050 0.2352
HGP 0.000 0.078 0.051 0.222 0.453 1.593
0.068 0.111 0.082 4.804 7.012 6.030
0.9990 0.4875 0.5339 0.9630 0.9490 0.7931
Hepatic IR 1.222 0.865 0.262 154.2 527.8 565.4
4.012 10.31 5.149 283.6 653.4 387.0
0.7625 0.9336 0.9600 0.5902 0.4247 0.1532
GOX 0.115 0.085 0.129 0.371 4.375 13.61
0.111 0.159 0.099 7.973 10.82 7.284
0.3070 0.5973 0.1990 0.9630 0.6883 0.0704
FOX 0.048 0.130 0.057 0.678 4.477 5.303
0.065 0.068 0.051 4.604 4.455 3.854
0.4640 0.0634 0.2790 0.8840 0.3219 0.1780
Insulin-stimulated
M-value 0.306 0.974 0.016 2.371 69.74 7.566
0.286 0.547 0.289 21.08 34.32 21.17
0.2920 0.0842 0.9560 0.9111 0.0500 0.7230
0.1827
GOX 0.032 0.191 0.166 1.444 30.09 7.168
0.122 0.196 0.128 9.430 10.84 9.759
0.7930 0.3350 0.2040 0.8790 0.0088 0.4680
0.0616
FOX 0.017 0.012 0.041 2.894 12.19 7.563
0.053 0.068 0.050 4.043 3.781 3.517
0.7430 0.8619 0.4210 0.4790 0.0027 0.0394
0.0378 0.2760
IVGTT
FPIR 100.5 202.2 181.9 4261 8831 1.0 E4
113.5 309.3 94.15 8032 2.1 E4 7553
0.3819 0.5175 0.0618 0.5992 0.6700 0.1880
(Continued)
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oxidation rate and a lower glucose oxidation rate during
sleep on the control diet compared with NBW men
(Table 2). Also, LBW and NBW men both increased fatty
acid oxidation rates and decreased protein oxidation rates
in all measured time intervals during the 24 h calorimetry
in response to overfeeding, and NBW men decreased the
glucose oxidation rate during day time due this challenge
(Table 2). Furthermore, LBW and NBW men both
increased total energy expenditures in response to over-
feeding (Table 2). LBW men had a higher hepatic insulin
resistance index after the control diet compared with
NBW men, but LBW and NBW men did not have a dif-
ferent insulin-stimulated glucose infusion rate, M-value,
after this diet (Table 1). Furthermore, NBW men
increased the hepatic insulin resistance index in response
to overfeeding, whereas LBW men decreased the M-value
in reaction to overfeeding. LBW and NBW men did not
show a different first-phase insulin response (FPIR) and
nor different hepatic or peripheral disposition indices
(DI) following the control or high-fat, high-calorie diet
(Table 1). However, LBW and NBW men both increased
the FPIR in response to overfeeding, and NBW men addi-
tionally increased the peripheral DI due to this challenge.
Acylcarnitine levels and their relation to
physiological measures
Low birth weight and NBW men showed differences in
plasma acylcarnitine levels after the control diet, but not
after the high-fat, high-calorie diet, and both birth weight
groups furthermore showed changes in acylcarnitine levels
in response to overfeeding (Table 3).
Low birth weight men had higher C2, C4-OH,
C6-DC, and C10-OH/C8-DC levels after the control
diet compared with NBW men, and they also displayed
higher total hydroxyl-/dicarboxyl-acylcarnitine and total
acylcarnitine levels after this diet. However, LBW men
did not have a higher total acylcarnitine level when C2
was excluded from the sum (data not shown). Further-
more, LBW and NBW men both decreased C2, C12:1,
C16:2, C16:1, C16, C18:1, C18, C18:1-OH/C16:1-DC,
and total acylcarnitine levels in response to overfeeding.
LBW men additionally decreased C4/C4i, C4-OH, C10-
OH/C8-DC, and C14:1 levels when exposed to overfeed-
ing, whereas NBW men decreased C12-OH/C10-DC,
C14:2, and C16:1-OH/C14:1-DC levels due to this chal-
lenge. Moreover, LBW and NBW men both increased
C8:1 and C8:1-OH/C6:1-DC levels in response to over-
feeding. Also, LBW men increased the C10:3 level,
whereas NBW men increased C6-DC and C22 levels
due to overfeeding.
C10-OH/C8-DC, total hydroxyl-/dicarboxyl-acylcarni-
tine, and total acylcarnitine levels were positively associ-
ated with the plasma nonesterified fatty acid level after
the control diet (Tables 5 and 6). Also, C10-OH/C8-DC
and total hydroxyl-/dicarboxyl-acylcarnitine levels tended
to be negatively associated with the serum insulin level
after the control diet. In addition, the C10-OH/C8-DC
level tended to be positively associated with the M-value
after the control diet, and the total hydroxyl-/dicarboxyl-
acylcarnitine level tended to be negatively associated with
the hepatic insulin resistance index after this diet. Fur-
thermore, the C4-OH level was positively associated with
the insulin-stimulated glucose oxidation rate and nega-
tively associated with the insulin-stimulated fatty acid oxi-
dation rate after the high-fat, high-calorie diet, and
tended to be positively associated with the M-value
after this diet (Table 4). Moreover, a decrease in total
hydroxyl-/dicarboxyl-acylcarnitine and total acylcarnitine
levels in response to overfeeding was associated with a
decrease in the plasma nonesterified fatty acid level, and a
decrease in the total hydroxyl-/dicarboxyl-acylcarnitine
Table 4. Continued.
C2
(Slope, SD, P, Q)
C4-OH
(Slope, SD, P, Q)
C O D C O D
Hepatic DI 0.012 0.011 0.029 0.953 1.588 2.153
0.016 0.032 0.013 1.062 2.107 1.044
0.4430 0.7230 0.0336 0.3760 0.4560 0.0470
0.2352 0.2760
Peripheral DI 0.021 0.031 0.026 1.774 0.2400 2.457
0.016 0.037 0.018 1.081 2.423 1.358
0.1950 0.4080 0.1480 0.1104 0.9220 0.0795
Data are presented as slope, SD, and P-value. P-values ≤0.05 are presented together with Q-values, and P-values ≤0.05 with corresponding Q-
values ≤0.1 are considered statistically significant. P-values ≤0.05 and Q-values ≤0.1 are marked in bold. Regression analyses were performed
on the pooled data set of LBW and NBW individuals and were adjusted for age, BMI, and birth weight group. Abbreviations: See Table 1.
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Table 5. Associations between C6-DC or C10-OH/C8-DC level and physiological measures following the control (C) and high-fat, high-calorie
(O) diets and between response values (D).
C6-DC
(Slope, SD, P, Q)
C10-OH/C8-DC
(Slope, SD, P, Q)
C O D C O D
Lipid profiling
P-TG 0.893 1.170 5.201 1.976 0.774 5.816
2.298 1.847 2.184 3.209 3.828 3.574
0.6999 0.5302 0.0227 0.5420 0.8410 0.1124
0.1589
Clamp
Basal
B-Glucose 1.683 5.724 2.958 7.441 9.371 4.710
3.409 2.404 2.522 4.689 4.895 3.395
0.6245 0.0226 0.2487 0.1211 0.0635 0.2392
0.1848
S-Insulin 113.9 45.45 16.15 257.4 64.69 47.87
77.68 96.33 70.67 102.1 225.3 114.1
0.1512 0.6402 0.8210 0.0162 0.7760 0.6780
0.1134
P-NEFA 2775 138.1 801.9 5505 894.5 3793
992.8 602.5 978.8 1338 1169 1423
0.0082 0.8200 0.4180 0.0002 0.4490 0.0114
0.1148 0.0028 0.1596
HGP 0.662 3.164 1.891 2.140 6.143 8.350
3.900 3.712 4.235 5.419 7.286 6.613
0.8660 0.3994 0.6578 0.6950 0.4050 0.2140
Hepatic IR 296.3 3561 125.2 397.3 353.2 681.8
224.6 336.6 268.9 315.9 760.8 416.6
0.1956 0.2973 0.6440 0.2168 0.6454 0.1110
GOX 11.80 3.977 10.08 14.41 0.277 12.05
6.210 5.189 5.197 8.846 10.78 8.477
0.0654 0.4486 0.0608 0.1120 0.9796 0.1640
FOX 7.191 5.105 6.744 6.254 7.978 7.003
3.567 2.203 2.627 5.190 4.642 4.322
0.0513 0.0264 0.0148 0.2360 0.0945 0.1140
0.1848 0.1589
Insulin-stimulated
M-value 33.49 20.55 5.711 46.84 23.39 1.585
17.21 18.70 15.25 21.59 37.19 23.35
0.0595 0.2793 0.7104 0.0367 0.5336 0.9463
0.1713
GOX 1.617 5.470 1.158 2.194 23.63 12.30
7.505 6.240 6.853 11.41 12.31 11.49
0.8310 0.3867 0.8670 0.8490 0.0630 0.2930
FOX 2.189 1.103 0.904 1.085 0.947 1.110
3.222 2.237 2.642 4.930 4.599 4.451
0.5020 0.6249 0.7350 0.8270 0.8380 0.8047
IVGTT
FPIR 4457 1.4 E4 8198 1.0 E4 1.8 E4 1.3 E4
6603 1.0 E4 5370 9035 2.0 E4 8439
0.5043 0.1780 0.1361 0.2615 0.3572 0.1193
(Continued)
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level was additionally associated with a decrease in the
plasma triacylglycerol level and an increase in FPIR.
Discussion
In order to investigate a possible differential and poten-
tially incomplete fatty acid oxidation in LBW individuals,
we measured fasting plasma levels of 45 acylcarnitine spe-
cies or sets of species in 18 LBW and 25 NBW men fol-
lowing an isocaloric control diet and a 5-day high-fat,
high-calorie diet.
We demonstrated that LBW men had higher C2, C4-
OH, C6-DC, and C10-OH/C8-DC levels after the control
diet compared with NBW men, and also a higher total
hydroxyl-/dicarboxyl-acylcarnitine level after this diet.
Moreover, C10-OH/C8-DC and total hydroxyl-/dicar-
boxyl-acylcarnitine levels tended to be negatively associ-
ated with the serum insulin level after the control diet,
and the total hydroxyl-/dicarboxyl-acylcarnitine level
additionally tended to be negatively associated with the
hepatic insulin resistance index after this diet.
Low birth weight individuals’ higher C2 level after the
control diet is reflective of an excess of acetyl-CoA in the
mitochondrial matrix. This indicates increased fatty acid,
glucose, and/or amino acid oxidation rates relative to the
TCA cycle flux (Fig. 1). Also, their unaltered total acylcar-
nitine level when excluding C2 suggests that they do not
have limitations in fatty acid beta-oxidation. In previous
studies, we have found that LBW men have an increased
fatty acid oxidation rate and a decreased glucose oxida-
tion rate at night time during the control diet compared
with NBW men, whereas they do not have a different
protein oxidation rate (Brons et al. 2013). Thus, an accu-
mulation of acetyl-CoA in LBW men is likely to be due
to an increased fatty acid beta-oxidation. Furthermore, we
have shown that LBW and NBW men do not show differ-
ences in expression levels of genes involved in oxidative
phosphorylation or differences in ATP synthesis in skele-
tal muscle (Brons et al. 2008). Thus, at least in skeletal
muscle, available data indicate that LBW individuals
could have an increased beta-oxidation rate and an
unchanged TCA cycle flux, which would cause an accu-
mulation of acetyl-CoA in the mitochondrial matrix
(Fig. 1). Their higher 3-hydroxy-butyrylcarnitine, C4-OH,
level is thought to reflect ketogenesis (McGarry and Fos-
ter 1972), consistent with an excess pool of acetyl-CoA.
As the liver is a primary site of ketogenesis, these findings
may suggest increased rates of hepatic fatty acid oxidation
in LBW men (Fig. 1). Hydroxyl- and dicarboxyl-fatty
acids are products of fatty acid omega-oxidation in the
endoplasmic reticulum of mainly the liver (Reddy and
Hashimoto 2001), and with regards to medium-chain
dicarboxyl-fatty acids and their acylcarnitine esters, in
addition of beta-oxidation in peroxisomes, as long-chain
dicarboxyl-fatty acids derived from omega-oxidation are
oxidized in peroxisomes (Houten et al. 2012). Omega-
oxidation is a minor route for oxidation of fatty acids
under normal physiological conditions (Reddy and Hashi-
moto 2001; Patsouris et al. 2006). However, the flux of
fatty acids through this pathway is increased when intra-
cellular levels of nonesterified fatty acids are high such as
following high-fat feeding (Patsouris et al. 2006) or under
fasting (Patsouris et al. 2006) and starvation (Bjorkhem
1976; Kroetz et al. 1998). In addition to the omega-oxida-
tion pathway, hydroxyl-fatty acids are intermediates in
beta-oxidation in mitochondria and peroxisomes (Reddy
and Hashimoto 2001; Jones and Bennett 2010). Therefore,
the higher C6-DC, C10-OH/C8-DC, and total hydroxyl-/
dicarboxyl-acylcarnitine levels in LBW men could reflect
an increased omega-oxidation (Mortensen and Gregersen
1981) along with an increased beta-oxidation of dicar-
boxyl-fatty acids (Houten et al. 2012) (Fig. 1), if these
acylcarnitines are in fact both hydroxyl- and dicarboxyl-
species, or, alternatively, an accumulation of intermediates
Table 5. Continued.
C6-DC
(Slope, SD, P, Q)
C10-OH/C8-DC
(Slope, SD, P, Q)
C O D C O D
Hepatic DI 0.350 0.433 0.131 0.483 0.794 0.566
0.926 1.029 0.730 1.277 2.111 1.160
0.7080 0.6770 0.8590 0.7080 0.7090 0.6290
Peripheral DI 0.2370 0.119 0.267 0.192 3.438 1.464
0.9630 1.193 1.024 1.329 2.437 1.585
0.8070 0.9210 0.7960 0.8860 0.1672 0.3620
Data are presented as slope, SD, and P-value. P-values ≤0.05 are presented together with Q-values, and P-values ≤0.05 with corresponding Q-
values ≤0.1 are considered statistically significant. P-values ≤0.05 and Q-values ≤0.1 are marked in bold. Regression analyses were performed
on the pooled data set of LBW and NBW individuals and were adjusted for age, BMI, and birth weight group. Abbreviations: See Table 1.
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Table 6. Associations between total OH-/DC-acylcarnitine, total non-OH-/DC-acylcarnitine, or total acylcarnitine level and physiological mea-
sures following the control (C) and high-fat, high-calorie (O) diets and between response values (D).
OH/DC-acylcarnitines
(Slope, SD, P, Q)
Non-OH/DC-acylcarnitines
(Slope, SD, P, Q)
All acylcarnitines
(Slope, SD, P, Q)
C O D C O D C O D
Lipid profiling
P-TG 0.210 0.714 2.119 0.045 0.101 0.071 0.042 0.099 0.074
0.787 0.584 0.696 0.033 0.045 0.041 0.033 0.043 0.039
0.7910 0.2294 0.0043 0.1888 0.0308 0.0893 0.2040 0.0285 0.0697
0.0315 0.2793 0.2772
Clamp
Basal
B-Glucose 1.605 1.190 0.246 0.014 0.665 0.047 0.016 0.068 0.045
1.142 0.786 0.920 0.050 0.064 0.043 0.049 0.061 0.043
0.1681 0.1387 0.7912 0.7778 0.3181 0.2898 0.7393 0.2781 0.2944
S-Insulin 54.46 0.031 5.130 0.307 1.698 1.171 0.389 1.607 1.131
25.91 32.60 25.37 1.184 2.446 1.240 1.156 2.381 1.212
0.0427 0.9920 0.8410 0.7970 0.4930 0.3520 0.7382 0.5050 0.3580
0.1993
P-NEFA 1044 153.9 887.4 49.78 30.20 48.20 49.68 29.34 48.66
339.9 188.6 292.7 15.62 14.16 15.81 15.18 13.74 15.34
0.0040 0.4200 0.0045 0.0029 0.0399 0.0043 0.0023 0.0396 0.0031
0.0560 0.0315 0.0406 0.2793 0.0602 0.0322 0.2772 0.0434
HGP 0.402 0.212 0.191 0.009 0.052 0.042 0.008 0.047 0.039
1.326 1.155 1.507 0.058 0.093 0.077 0.057 0.090 0.075
0.7640 0.8551 0.8999 0.8710 0.5819 0.5910 0.8840 0.6040 0.6041
Hepatic IR 160.9 22.89 20.38 1.182 0.209 1.137 0.835 0.324 1.131
73.23 114.1 95.36 3.400 8.697 4.678 3.323 8.461 4.568
0.0347 0.8422 0.8320 0.7302 0.9810 0.8090 0.8030 0.9697 0.8060
0.1993
GOX 2.652 0.924 4.280 0.125 0.062 0.147 0.124 0.053 0.150
2.156 1.759 2.032 0.094 0.136 0.091 0.092 0.131 0.089
0.2270 0.6025 0.0426 0.1920 0.6514 0.1160 0.1840 0.6906 0.1020
0.1491
FOX 1.159 0.930 1.899 0.056 0.105 0.071 0.056 0.104 0.073
1.256 0.772 1.017 0.055 0.057 0.048 0.053 0.055 0.047
0.3620 0.2365 0.0704 0.3120 0.0736 0.1470 0.3040 0.0673 0.1310
Insulin-stimulated
M-value 10.20 4.765 2.950 0.332 0.799 0.012 0.334 0.776 0.004
5.593 5.715 5.392 0.241 0.450 0.276 0.235 0.435 0.271
0.0764 0.4102 0.5879 0.1770 0.0848 0.9669 0.1640 0.0832 0.9890
GOX 0.568 5.344 2.610 0.030 0.245 0.136 0.028 0.259 0.126
2.590 1.917 2.603 0.105 0.160 0.123 0.102 0.153 0.121
0.8280 0.0085 0.3240 0.7750 0.1340 0.2750 0.7870 0.0994 0.3050
0.1190
FOX 0.509 0.772 1.380 0.019 0.034 0.032 0.017 0.036 0.028
1.116 0.739 0.993 0.045 0.056 0.047 0.044 0.055 0.047
0.6510 0.3035 0.1743 0.6810 0.5513 0.4987 0.7020 0.5124 0.5466
IVGTT
FPIR 1437 4583 4802 1037 232.8 198.0 101.4 246.1 201.0
2214 3368 1810 95.87 260.0 85.64 93.56 252.7 83.68
0.5206 0.1820 0.0120 0.2871 0.3765 0.0270 0.2862 0.3368 0.0219
(Continued)
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in beta-oxidation pathways, if the pooled species are com-
prised solely or predominantly of the hydroxyl-species.
Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analyses will be required to resolve this issue, as
opposed to the flow injection-MS/MS analyses conducted
herein. White adipose tissue lipolysis is increased during
deficient adipose tissue insulin signaling, and we have
previously described this trait in LBW individuals (Alibe-
govic et al. 2010). Furthermore, our recent studies of adi-
pose tissue cells suggest that LBW is associated with an
impaired development of subcutaneous adipose tissue
(Ferland-McCollough et al. 2012; Schultz et al. 2014). An
increased lipolysis results in a shift in the equilibrium of
fat storage from adipose tissue toward an increased stor-
age in nonadipose tissue such as the liver (Samuel and
Shulman 2016). Also, an increased hepatic fatty acid load
is expected to induce omega-oxidation (Patsouris et al.
2006). Interestingly, omega-oxidation has been shown to
be upregulated in experimental models of diabetes (Yosh-
ioka et al. 1994; Miura 2013) as well as in patients with
diabetes (Lippe et al. 1987). This, together with the pre-
sent findings of a possible increase in omega-oxidation in
LBW individuals, suggests that an increased omega-oxida-
tion could be part of the metabolic phenotype of predia-
betes and diabetes.
Acetylcarnitine, C2, has been reported to be a marker
of prediabetes (Wang-Sattler et al. 2012), and an ele-
vated fasting plasma C2 level has been found in adults
with type 2 diabetes (Adams et al. 2009; Villarreal-Perez
et al. 2014). Also, the fasting plasma C2 level has been
shown to positively associate with the fasting plasma
HbA1c level in women with or without diabetes (Adams
et al. 2009). However, in this study, the C2 level did
not associate with measures of insulin secretion or sensi-
tivity. In addition, the fasting plasma C4-OH level has
been found to be elevated in obese women with type 2
diabetes (Fiehn et al. 2010). Furthermore, the fatty acid
moiety of this acylcarnitine has been shown to interfere
with insulin signaling (Tardif et al. 2001), and its levels
in skeletal muscle have been associated with muscle
insulin resistance in diet-induced obesity rodent models
(An et al. 2004). In this study, we did not observe any
associations between the plasma C4-OH level and insulin
secretion or sensitivity. However, C10-OH/C8-DC and
total hydroxyl-/dicarboxyl-acylcarnitine levels tended to
be negatively associated with the serum insulin level,
and the total hydroxyl-/dicarboxyl-acylcarnitine level
additionally tended to be negatively associated with the
hepatic insulin resistance index. This suggests that
omega-oxidation could act as a scavenger pathway for
oxidation of fatty acids when intracellular acyl-CoA
levels are high to thereby reduce the availability of these
precursors for the synthesis of lipotoxic lipid species
such as ceramides and diacylglycerols that impair insulin
signaling (Chavez and Summers 2012; Jornayvaz and
Shulman 2012) (Fig. 1).
We furthermore demonstrated that LBW and NBW
men decreased levels of 12 and 11 of the measured acyl-
carnitine species, respectively, as well as the total acylcar-
nitine level in response to overfeeding. In addition, they
increased levels of three and four species, respectively,
due to this challenge.
Low birth weight and NBW individuals’ decrease in
several short-, medium-, and long-chain acylcarnitine spe-
cies, including C2, in response to overfeeding could be
due to an increased fatty acid beta-oxidation and TCA
cycle flux following the high-fat, high-calorie diet com-
pared to the control diet. This interpretation is strongly
supported by the findings that LBW and NBW men
increased both fatty acid oxidation rates and total energy
Table 6. Continued.
OH/DC-acylcarnitines
(Slope, SD, P, Q)
Non-OH/DC-acylcarnitines
(Slope, SD, P, Q)
All acylcarnitines
(Slope, SD, P, Q)
C O D C O D C O D
0.0560 0.1549 0.1533
Hepatic DI 0.043 0.136 0.055 0.011 0.012 0.027 0.010 0.013 0.026
0.308 0.347 0.269 0.013 0.027 0.012 0.013 0.026 0.012
0.8890 0.6970 0.8380 0.4320 0.6470 0.0332 0.4390 0.6350 0.0357
0.1549 0.1666
Peripheral DI 0.185 0.451 0.329 0.016 0.030 0.023 0.016 0.031 0.023
0.323 0.393 0.363 0.014 0.031 0.017 0.014 0.030 0.016
0.5710 0.2590 0.3720 0.2490 0.3450 0.1700 0.2500 0.3150 0.1640
Data are presented as slope, SD, and P-value. P-values ≤0.05 are presented together with Q-values, and P-values ≤0.05 with corresponding Q-
values ≤0.1 are considered statistically significant. P-values ≤0.05 and Q-values ≤0.1 are marked in bold. Regression analyses were performed on
the pooled dataset of LBW and NBW individuals and were adjusted for age, body mass index, and birth weight group. Abbreviations: See Table 1.
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Figure 1. Proposed differences in fatty acid oxidation pathways between low (LBW) and normal birth weight (NBW) individuals. LBW
individuals may have an increased beta-oxidation in mitochondria of skeletal muscle (upper panel) and liver (bottom panel) that is not matched
by an equivalently increased TCA cycle flux, resulting in an accumulation of acetyl-CoA in the mitochondrial matrix and following of
acetylcarnitine in the cytosol. Also, an excess of acetyl-CoA could lead to an increased ketogenesis in the liver and following an accumulation
of 3-hydroxy-butyrylcarnitine (not shown). Furthermore, LBW individuals may have an increased omega-oxidation in the endoplasmic reticulum
of the liver along with an increased beta-oxidation of dicarboxyl-fatty acids in peroxisomes, leading to an accumulation of hydroxyl- and
dicarboxyl-acylcarnitine species. Omega-oxidation may be a scavenger pathway for oxidation of fatty acids that otherwise could be available for
synthesis of lipotoxic lipid species such as ceramides and diacylglycerols that impair insulin signaling.
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expenditures during all time intervals of the 24 h
calorimetry in response to overfeeding, and furthermore
from the finding that they reduced the plasma nonesteri-
fied fatty acid level due to this challenge (Brons et al.
2012). In a prior rodent study, mice fed a high-fat diet
had higher serum levels of several medium- and long-
chain acylcarnitines compared with mice fed a standard
diet (Koves et al. 2008). It was suggested that the high-fat
feeding resulted in an incomplete fatty acid beta-oxidation
(Koves et al. 2008). However, in this study, the high-fat
overfeeding was for only 5 days and the blood samples
were collected after an overnight fast, as opposite to the
rodent study in which the intervention was for 12 weeks,
and the samples were collected in the fed state (Koves
et al. 2008). Thus, an increased beta-oxidation and TCA
cycle flux in response to short-term high-fat overfeeding
could be a compensatory mechanism to prevent an accu-
mulation of lipids in nonadipose tissue. Such a mecha-
nism is probably only transient and may not persist for
long-term high-fat overfeeding exposure. This hypothesis,
however, requires further studies. Their increase in C8:1
and C8:1-OH/C6:1-DC levels in response to overfeeding
may be explained by the markedly higher n-3 fatty acid
content in the high-fat, high-calorie diet compared to the
control diet (Table S1), as C8:1 and C6:1 n-3 fatty acids
are oxidation products of several n-3 fatty acids, including
alpha-linolenic acid, C18:3 n-3 fatty acid.
Our study is the first to describe fasting plasma acylcar-
nitine levels in LBW individuals with an increased risk of
developing type 2 diabetes. It has its strengths in the care-
ful selection of LBW and NBW men, highly standardized
study setup, and in depth physiological and metabolic
characterization of the individuals. In relation to the bio-
logical interpretation of the results, however, it has its
limitations in the acylcarnitine profiling being on the
plasma level, as plasma acylcarnitines represent the sum
of contributions of acylcarnitines from various tissues,
mainly skeletal muscle and liver, that may respond differ-
ently to a given metabolic challenge (Schooneman et al.
2013, 2014). Also, plasma and these tissues may have dif-
ferent turnover rates of acylcarnitines (Schooneman et al.
2014). In summary, we demonstrated that LBW men had
higher C2 and C4-OH levels after the control diet com-
pared with NBW men, suggestive of an increased fatty
acid beta-oxidation in mitochondria relative to the TCA
cycle flux. Furthermore, we showed that LBW men had
higher C6-DC, C10-OH/C8-DC, and total hydroxyl-/
dicarboxyl-acylcarnitine levels, which may suggest an
increased fatty acid omega-oxidation in the endoplasmic
reticulum of the liver concomitant with an increased
beta-oxidation in peroxisomes of omega-oxidation-
derived dicarboxyl-fatty acids. Interestingly, a cluster of
short-chain, dicarboxyl-acylcarnitine species, including
C6-DC, has recently been shown to be prognostic for
myocardial infarction and all-cause cardiac mortality
(Shah et al. 2010, 2012). Moreover, we found that C10-
OH/C8-DC and total hydroxyl-/dicarboxyl-acylcarnitine
levels tended to be negatively associated with the serum
insulin level, and the total hydroxyl-/dicarboxyl-acylcarni-
tine level additionally tended to be negatively associated
with the hepatic insulin resistance index. Therefore, we
proposed that an increased fatty acid omega-oxidation
could prevent an accumulation of lipotoxic lipid species
that impair insulin signaling in the liver. Intervention
studies that aim to increase the efficiency of fatty acid
oxidation, including hepatic omega-oxidation, and TCA
cycle flux to thereby potentially reduce an accumulation
of lipids and improve insulin action in LBW individuals
are needed.
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